异搏定和肿瘤坏死因子α协同抗肿瘤作用的实验研究  

Synergic antitumor effect of verapamil and tumor necrosis factor alpha

作　　者：张红[1] 侯蜀新[1] 李碗定 李进义[1] 

机构地区：[1]暨南大学医学院第一附属医院外科,广东广州510632 [2]中华人民共和国澳门特别行政区卫生局仁伯爵综合医院

出　　处：《中国病理生理杂志》2001年第7期639-643,共5页Chinese Journal of Pathophysiology

摘　　要：目的 :研究异搏定和肿瘤坏死因子α(TNFα)对肝癌的协同作用。方法 :利用人肝癌HepG2 体外培养及裸鼠皮下移植模型 ,在异搏定、肿瘤坏死因子以及异搏定和肿瘤坏死因子同时存在的条件下 ,观察肿瘤细胞增殖及肿瘤组织生长状况、c-myc表达肿瘤组织的细胞增殖核抗原 (PCNA)检验以及肿瘤组织微血管密度 (MVD)的比较。结果 :在异搏定以及异搏定和TNFα同时存在的条件下 ,HepG2 的增殖及移植肿瘤的生长受到明显抑制 ;c -myc的表达、PCNA的表达以及MVD明显降低。结论 :钙通道阻滞剂可抑制肿瘤的增殖与生长 ;异搏定与TNFα有显著的协同抗肿瘤作用。AIM: To study the synergic antitumor effect of verapamil (VPL) and tumor necrosis factor alpha (TNFα). METHODS: In the presence of verapamil or verapami plus tumor necrosis factor, the proliferation, the expressions of c-myc and PCNA, the mean vessel density(MVD)of human hepatoma cell line(HepG 2) were studied in vivo and in vitro. RESULTS: It was demonstrated that the growth of HepG 2 was inhibited remarkably, under the presence of verapamil and TNFα simutaneously, the expressions of c-myc , PCNA and the MVD were also decreased. CONCLUSION: The calcium channel blocker can inhibit the proliferation of tumor and has a remarkable synergy with TNFα. [

关 键 词：异搏定 肿瘤坏死因子Α 抗肿瘤 实验 肝癌 钙离子拮抗剂 

分 类 号：R735.7[医药卫生—肿瘤] R73-36[医药卫生—临床医学]